KYTX - Kyverna Therapeutics, Inc Average Forecast Price
Kyverna Therapeutics (KYTX) possesses immense pricing power, as the development of radical cure methods will enable the company to demand multi-million dollar payments from insurers. This promising cell therapy player has earned recognition for innovations in treating systemic pathologies. This price chart, where the metric stands at 30.45, complements data on the use of cryo-containers to ensure the safest possible delivery of biomaterials to patients.
Analytical breakdowns for Kyverna (KYTX)
- stock value and consensus price forecast:
- market capitalization statistics:
- shareholders' equity book value data:
- business debt structure and liquidity details:
Aggregate Debt to Equity Kyverna Therapeutics|KYTX - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Kyverna Therapeutics, Inc|KYTX - Company Aggregate Debts|Debts to Book Capitalization Kyverna|KYTX - Company Long-Term Debt|Company Short-Term Loans and Borrowings Kyverna Therapeutics|Quick Liquidity Indicator kyvernatx.com
- earnings and market ratios statistics:
KYTX - Net Profit|Projected Future Earnings Kyverna Therapeutics|KYTX - Price to Earnings Ratio|Future Price to Earnings Multiple Kyverna Therapeutics Inc.|KYTX - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Kyverna|KYTX - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Kyverna Therapeutics|KYTX - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months kyvernatx.com|KYTX - Net earnings per share growth this year|Earnings growth forecast for next year Kyverna Therapeutics
General company analysis:KYTX kyvernatx.com
The stability of the R&D core at Kyverna Therapeutics (KYTX) within the CAR-T therapy sector should be reflected in the average target price, confirming market confidence in the company's human capital. This indicator represents the aggregated average of leading analysts' forecasts, enabling the timely detection of hidden fundamental downgrades and helping investors avoid value traps when attempting to purchase the asset at local bottoms.
Competitors of Kyverna Therapeutics
Analyst Consensus Forecast argenx.com (ARGX)|BioNTech - Consensus Target|Abivax SA (ABVX) - Average Forecast Price|ADMA: Consensus Target|Protagonist Corp - Analyst Forecast Prices|IMVT (Immunovant, Inc.) - Consensus Target|Broker Consensus Forecast KNSA|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|JBIO - Price Target Chart|ACRS - Analyst Consensus Forecast|TLSA (Tiziana Life Sciences) - Consensus Target|Average Forecast Price cabalettabio.com (CABA)|Consensus Target VTYX|Price Target Chart THTX|Analyst Consensus Forecast AVTX|ELDN - Average Forecast Price|Price Target Chart Agenus AGEN|Fair Value Consensus CLYM|ZURA - Price Target Chart|ATYR (aTyr Pharma Inc) - Broker Consensus Forecast|ADAG: Analyst Consensus Forecast|Ikena Oncology (IMA) - Analyst Consensus Forecast|Consensus Target STTK|EQ: Fair Value Consensus|Consensus Target CNTB (Connect Biopharma)|Analyst Forecast Prices IMUX|Analyst Consensus Forecast ATRA (Atara Bio)|Fair Value Consensus IFRX|X4 Pharmaceuticals - Analyst Consensus Forecast|Average Forecast Price Adicet Bio|celularity.com (CELU) - Price Target Chart|INmune Bio Inc - Fair Value Consensus|BRNS (Barinthus Bio) - Analyst Consensus Forecast|Analyst Consensus Forecast Kezar Life Sciences Inc|Price Target Chart SAB Biotherapeutics (SABS)|AKTX: Forecast Levels Chart|Analyst Consensus Forecast ENLV (Enlivex Therapeutics Ltd.)|Q32 Bio Inc (QTTB) - Average Forecast Price|GOVX: Consensus Target|EDSA - Analyst Consensus Forecast|IBIO (iBio, Inc.) - Consensus Target|CARM: Analyst Forecast Prices|XTLB (XTL Biopharmaceuticals Ltd.) - Analyst Consensus Forecast|Bolt Bio (BOLT) - Analyst Median Target|Analyst Consensus Forecast HCWB|Consensus Target aptevotherapeutics.com APVO|Price Target Chart AIM ImmunoTech AIM|Analyst Median Target Aditxt Inc. (ADTX)|GRI - Price Target Chart|XRTX - Analyst Consensus Forecast|HIND (ReShape Lifesciences) - Consensus Target|Average Forecast Price Revelation Biosciences Corp (REVB)|Consensus Target INDP|SCNI (scinai.com) - Analyst Forecast Prices|Consensus Target CALI (CalciMedica, Inc.)|affimed.com - Broker Consensus Forecast|Price Target Chart Allakos ALLK|HOOK (HOOKIPA Pharma, Inc.) - Forecast Levels Chart|IGM Bio - Analyst Consensus Forecast|Fair Value Consensus ITOS (iteostherapeutics.com)|OCEA: Analyst Consensus Forecast|TC BioPharm (Holdings) Plc (TCBP) - Analyst Consensus Forecast|Price Target Chart Third Harmonic Bio, Inc
